Skip to content

The effects of single session Competitive Memory Training (COMET) and yohimbine on the saliency of positive autobiographical memories.

The effects of single session Competitive Memory Training (COMET) and yohimbine on the saliency of positive autobiographical memories.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25731
Enrollment
30
Registered
2017-10-15
Start date
2017-02-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Positive autobiographical memories COMET Yohimbine Positieve autobiografische herinneringen

Interventions

Participants select four mildly positive autobiographical memories. They receive two intervention sessions. During each session, one memory will be activated using COMET procedures and one memory will

Sponsors

Prof. dr. Marcel A. van den Hout Utrecht University Faculty of Social Sciences Division of Clinical Psychology Heidelberglaan 1 3584 CS Utrecht University Tel: 0031302531793 m.a.vandenhout@uu.nl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Age 18-30 - Written informed consent - Body Mass Index (BMI) between 17.5 and 26 - Passing the medical screening (heart rate and blood pressure, medical interview) - In females: the use of reliable contraceptives (birth control pills or a hormonal intrauterine device)

Exclusion criteria

Exclusion criteria: Assessed by physical exam: - High blood pressure: systolic blood pressure over 140 mmHg, diastolic over 90 mmHg - High heart rate: >90 beats per minute (bpm) Assessed by interview: - Inability to adequately read or speak Dutch - Known sensitivity to yohimbine - History of affective psychiatric disorders in the past 2 years - Lifetime history of neurological disease (attention/memory disorders, epilepsy, convulsions) - Current attention/memory problems - Lifetime history of any cardiovascular problem, coronary insufficiency, congestive heart failure, heart block, tachycardia, myocardial infarction, hypertension, chronic obstructive pulmonary disease, bronchial asthma, renal disorders, liver disorders, diabetes - Early age cardiovascular problems in first degree family members - Fainting easily (can be indicative of cardiovascular problems) - Chronic or frequent migraines - Use of any medication - Use of anti-inflammatory painkillers in the past 3 weeks - Use of anxiolytics or antacids in the past week - A score of ≥ 26 on the Anxiety Sensitivity Index (ASI: Reiss, Peterson, Gursky, & McNally, 1986) (in order to eliminate individuals who might have difficulty with any temporary symptoms induced by the yohimbine manipulation). - Alcohol use of >2 units per day on one or more days during the past week - Any drug use during the past month - A score of ≥4 on the Fagerström Test for Nicotine Dependence (FTND: Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) (in order to eliminate individuals that are moderately or heavily dependent smokers).

Design outcomes

Primary

MeasureTime frame
Ease of recollection, specificity, vividness and positive affectivity of positive autobiographical memories at pre-test (baseline), post-test (after medication intake and COMET intervention) and 2-day follow-up measured with 100mm VASs.

Secondary

MeasureTime frame
Prior to and during the intervention, salivary α-amylase (sAA) levels, Skin Conductance Level (SCL) and Heart Rate (HR) are measured, as a manipulation check and in order to correlate noradrenaline/arousal levels with significant outcomes.

Contacts

Public ContactSuzanne Veen, van
s.c.vanveen@uu.nl0031302531470

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)